Carmell Therapeutics is addressing the burden of healing with its proprietary Plasma-based Bioactive Materials (PBM) technology
LAST MONEY IN OPPORTUNITY, $1M left of $7M bridge round to be converted at least at 20% discount and up to 40%! MAJOR FDA milestones!
Carmell is a clinical development stage company that is on path to gain US FDA & EU regulatory approval for its first Plasma-based Bioactive Material product, Bone Healing Accelerant, in the expanding market of orthopedic trauma. Spine fusion and shoulder rotator cuff repair will be added with label expansion.